Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer

Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer

Abstract Monotherapy with poly ADP-ribose polymerase (PARP) inhibitors results in a limited objective response rate (≤60% in most cases) in patients with homologous recombination repair (HRR)-deficient cancer, which suggests a high rate of resistance in this subset of patients to PARP inhibitors (PA...

Full description

Bibliographic Details
Main Authors: Ning Zhang, Yu-Nan Tian, Li-Na Zhou, Meng-Zhu Li, Hua-Dong Chen, Shan-Shan Song, Xia-Juan Huan, Xu-Bin Bao, Ao Zhang, Ze-Hong Miao, Jin-Xue He
Format: Article
Language:English
Published: Nature Publishing Group 2021-02-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-021-03475-4

Internet

https://doi.org/10.1038/s41419-021-03475-4

Similar Items